CLINICAL TRIALS PROFILE FOR ICP-022
✉ Email this page to a colleague
Clinical Trials for ICP-022
Trial ID | Title | Status | Sponsor | Phase | Summary |
---|---|---|---|---|---|
NCT03189017 ↗ | A Phase I Study of ICP-022 in Healthy Subjects | Completed | Innocare Pharma Australia Pty Ltd | Phase 1 | This is a single center, randomized, double-blind, placebo-controlled, dose escalation study in healthy subjects to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of ICP-022 following oral single and multiple escalating dose administration. |
NCT03493217 ↗ | A Study to Evaluate ICP-022 in Patients With CLL/ SLL | Active, not recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/Phase 2 | The phase I/II clinical study is to investigate the safety, tolerability and efficacy of ICP-022 in R/R CLL/SLL patients. |
NCT03494179 ↗ | A Study to Evaluate ICP-022 in Patients With R/R Mantle Cell Lymphoma (MCL) | Active, not recruiting | Beijing InnoCare Pharma Tech Co., Ltd. | Phase 1/Phase 2 | The phase I/II clinical study is to investigate the safety, tolerability and pharmacokinetics/ pharmacodynamics of ICP-022. |
>Trial ID | >Title | >Status | >Sponsor | >Phase | >Summary |
Clinical Trial Conditions for ICP-022
Condition Name
Clinical Trial Locations for ICP-022
Trials by Country
Clinical Trial Progress for ICP-022
Clinical Trial Phase
Clinical Trial Sponsors for ICP-022
Sponsor Name